Corcept Therapeutics (CORT) Current Assets (2010 - 2026)

Corcept Therapeutics has disclosed Current Assets across 17 years of filings, most recently posting $426.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $426.0 million, down 2.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $426.0 million (down 2.84% YoY), and the FY2025 annual result was $485.5 million, up 2.94% from the prior year.
• Current Assets came in at $426.0 million for Q1 2026 at Corcept Therapeutics, down from $485.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $560.8 million in Q2 2024 to a low of $388.2 million in Q1 2022.
• The 5-year median for Current Assets is $458.6 million (2023), against an average of $467.8 million.
• Across the five-year window, Current Assets surged 87.36% in 2022 and retreated 20.99% in 2025, its largest moves.
• Corcept Therapeutics' Current Assets stood at $499.3 million in 2022, then declined by 8.14% to $458.6 million in 2023, then gained by 2.83% to $471.6 million in 2024, then increased by 2.94% to $485.5 million in 2025, then decreased by 12.24% to $426.0 million in 2026.
• The last three Current Assets figures came in at $426.0 million (Q1 2026), $485.5 million (Q4 2025), and $541.1 million (Q3 2025), per Business Quant data.